NDATOPICALCREAM
Approved
Feb 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TZ-3 (tioconazole) is a topical antifungal cream approved by Pfizer in 1983 for the treatment of fungal skin infections. It is a small-molecule azole that disrupts fungal cell membrane integrity by inhibiting lanosterol demethylase. The product is a mature, off-patent therapy with established efficacy in dermatological indications.
LOE Approaching
As a mature product with LOE approaching, the brand team is likely focused on defending market share and managing cost-efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Started Jan 2026
42 enrolled
Non-Hodgkin Lymphoma Refractory/ RelapsedDLBCL - Diffuse Large B Cell LymphomaMantle Cell Lymphoma (MCL)+2 more
Career Relevance
TZ-3 offers limited career growth potential as a mature, off-patent topical with zero linked job openings and declining commercial relevance. Career development on this product is constrained; professionals should prioritize transitioning to growth-stage assets or pipeline candidates.
Brand Manager
Worked on TZ-3 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.